Case Group
OtherPatients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy.
NCT Number: NCT07341997
Peripheral neuropathies (PN) affect 1% of the global population, particularly the elderly. About 20-30% of cases remain unexplained. In French Guiana, we hypothesize that factors like neurotoxic traditional plant remedies, arboviral disease outbreaks, and mercury exposure from illegal gold mining may contribute to PN. The study aims to assess the association between PN and exposure to arboviral infections, heavy metals, and plant consumption in French Guiana.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Centre Hospitalier de Cayenne, Cayenne, French Guiana
Peripheral neuropathies (PN) affect 1% of the global population, with higher prevalence in the elderly. They lead to gait disorders and chronic pain, severely impacting quality of life. Despite thorough investigations, 20-30% of cases have no identified cause. In French Guiana, unique factors may contribute to these neuropathies, including the use of potentially neurotoxic traditional plant remedies and outbreaks of arboviral diseases, which can complicate conditions like Guillain-Barré syndrome. Additionally, illegal gold mining exposes residents to mercury, both directly and through environmental contamination. We hypothesize that these local factors might explain the unidentified cases of PN and exacerbate neuropathies in patients with pre-existing nerve vulnerability, such as diabetic neuropathy.
This is a prospective multicenter case-control study being conducted in hospitals in Cayenne and Saint-Laurent du Maroni. At the inclusion visit, blood samples will be taken to assess arbovirus serology, particularly for Zika, Chikungunya and Dengue, as well as to measure levels of heavy metals, including mercury and lead. In addition, urine and hair samples will be taken to analyze these heavy metals. Participants will also fill in a questionnaire about their plant consumption.
They will not be followed as part of the research.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy.
Time frame: At inclusion
The primary endpoint will be the comparison of rates of exposure to arboviruses, heavy metals and consumption of potentially neurotoxic plants in cases and controls.
The heavy metals assay and the questionnaire will be carried out at the inclusion visit.
Time frame: At inclusion
Secondary endpoint will be identification of genetic mutations responsible for peripheral neuropathy
Time frame: At inclusion
Secondary endpoint will be determination of Peripheral Nerve Disability (PND)
Contact information is provided by the study sponsor or research team.
Nathalie DESCHAMPS, Principal Investigator
CONTACT
Vincent De Paul SENEKIAN, Principal Investigator
CONTACT
Admin CIC
Other
Acronym: YANANER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06959277
Balance Control in Elderly, Gait Disorders
Mesa, Arizona, United States
View Trial DetailsNCT06807294
Chemotherapy Induced Peripheral Neuropathy (CIPN), Nervous System Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07268833
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS)
Monserrato, California, Italy
View Trial DetailsNCT07160270
Blood Protein Disorders, Cardiovascular Diseases
København Ø, Denmark
View Trial Details